Logo

Takeda Expands its License Agreement with Codexis to Discover Novel Gene Therapies for Fourth Rare Genetic Disorders

Share this

Takeda Expands its License Agreement with Codexis to Discover Novel Gene Therapies for Fourth Rare Genetic Disorders

Shots:

  • The companies expanded their license agreement for the research and development of an additional gene therapy for a lysosomal storage disorder. Takeda has exercised its option to initiate a fourth program based on the results from three initial programs
  • Following the Mar’2020 agreement- Codexis has created the novel enzyme sequences to advance gene therapies into pre-clinical development by utilizing its CodeEvolver protein engineering platform
  • Takeda is responsible for the pre/ clinical development and commercialization of gene therapy products emerges from the collaboration

  Ref: GlobeNewswire | Image: Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions